At the time of writing, Crinetics Pharmaceuticals Inc [CRNX] stock is trading at $40.47, up 4.65%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRNX shares have gain 8.15% over the last week, with a monthly amount glided 8.85%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 14, February 2024, Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024. In a post published today on Yahoo Finance, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a business update.
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on January 16, 2024, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $50. Previously, Jefferies started tracking the stock with Hold rating on December 21, 2023, and set its price target to $35. Oppenheimer initiated its recommendation with a Outperform and recommended $40 as its price target on August 31, 2023. Piper Sandler started tracking with a Overweight rating for this stock on April 24, 2023, and assigned it a price target of $56. In a note dated March 30, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $48 on this stock.
For the past year, the stock price of Crinetics Pharmaceuticals Inc fluctuated between $15.23 and $40.50. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $40.47 at the most recent close of the market. An investor can expect a potential drop of -2.4% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.05 points at the first support level, and at 37.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.34, and for the 2nd resistance point, it is at 42.21.
Crinetics Pharmaceuticals Inc [CRNX] reported earnings per share of -$1.01 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.86/share, meaning a difference of -$0.15 and a surprise factor of -17.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.94 per share as compared to estimates of -$0.86 per share, a difference of -$0.08 representing a surprise of -9.30%.
Ratios To Look Out For
It is important to note that Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] has a current ratio of 14.23. As well, the Quick Ratio is 14.23, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 3807.60, the price to book ratio is 4.93.
Transactions by insiders
Insider trading has also been a hot topic recently, with 0 insiders purchasing 0 shares and 1 selling 3,000 shares in the past 3 months. Recent insider trading involved Betz Stephen F., Chief Scientific Officer, that happened on Jan 25 when 3000.0 shares were sold. Chief Scientific Officer, Betz Stephen F. completed a deal on Jan 10 to sell 3000.0 shares. Meanwhile, Chief Med and Dev Officer Pizzuti Dana sold 14375.0 shares on Jan 03.
